Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic umbilical cord mesenchymal stromal cells (UC-MSCs) are multipotent progenitor cells harvested from the Wharton's jelly of human umbilical cords. These cells are characterized by their low immunogenicity and significant immunomodulatory potential, which they exert through the secretion of various cytokines, chemokines, and extracellular vesicles, as well as through direct cell-to-cell contact. In the treatment of type 1 diabetes mellitus, UC-MSCs aim to arrest the autoimmune destruction of insulin-producing pancreatic beta cells by shifting the immune response from a pro-inflammatory Th1/Th17 profile toward a regulatory T-cell (Treg) dominated environment. The Affiliated Nanjing Drum Tower Hospital is evaluating these cells in clinical trials to determine if repeated infusions can safely preserve residual C-peptide secretion and improve glycemic control in patients with recently diagnosed or established type 1 diabetes.
- Other names
- allogeneic umbilical cord-derived mesenchymal stromal cellsumbilical cord mesenchymal stem cellshUC-MSC
Beyond the preview
Go deeper on allogeneic umbilical cord mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord mesenchymal stromal cells.